Example orders for Cetuximab (Erbitux) in colon cancer

Hello!  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.  Please help us by filling it out!  Link: http://j.mp/2BlBaoQ

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.

Cetuximab (Erbitux)

Original references may be found at Cetuximab (Erbitux)

Example regimen #1

For cycle 1:

• Cetuximab (Erbitux) 400 mg/m² IV over 2 hours on day 1
  • Use non-DEHP/paclitaxel tubing.
• Cetuximab (Erbitux) 250 mg/m² IV over 60 minutes on days 8, 15, 22
  • Use non-DEHP/paclitaxel tubing.

28-day cycle

Supportive medications

• Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to cetuximab
• Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab

Hydration:

• 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

• Hold if ANC <1000 or platelets <100 and notify physician.

For cycle 2 and later:

• Cetuximab (Erbitux) 250 mg/m² IV over 60 minutes on days 1, 8, 15, 22
  • Use non-DEHP/paclitaxel tubing.

28-day cycles

Supportive medications

• Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to cetuximab
• Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab

Hydration:

• 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

• Hold if ANC <1000 or platelets <100 and notify physician.

Comments:

• My institution uses 28-day cycles for Cetuximab (Erbitux) regimens.